HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR - Free Report) in a research note published on Monday morning,Benzinga reports. They currently have a $35.00 price objective on the stock.
Other analysts have also recently issued reports about the company. Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $18.60.
Read Our Latest Analysis on Atyr PHARMA
Atyr PHARMA Price Performance
Shares of Atyr PHARMA stock traded down $0.05 on Monday, reaching $3.75. The company's stock had a trading volume of 991,820 shares, compared to its average volume of 931,298. The company has a market capitalization of $333.77 million, a P/E ratio of -3.99 and a beta of 0.79. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.66. The stock has a 50-day moving average price of $3.24 and a 200-day moving average price of $3.42. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Analysts expect that Atyr PHARMA will post -0.91 EPS for the current year.
Institutional Trading of Atyr PHARMA
Several large investors have recently added to or reduced their stakes in ATYR. JPMorgan Chase & Co. grew its holdings in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in Atyr PHARMA in the 4th quarter valued at $170,000. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter valued at $36,000. D.A. Davidson & CO. purchased a new stake in Atyr PHARMA in the 4th quarter valued at $141,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $144,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
